EFMC-ISMC 2014
Conferences > Archives > EFMC-ISMC 2014

Confirmed Speakers


Plenary Lectures

Medicinal Chemistry Experts in Pharma are Helping us to Generate Freely Available Novel Probes in Order to Facilitate Target Discovery
Prof. Chas BOUNTRAProf. Chas BOUNTRA
(UNIVERSITY OF OXFORD, Oxford, United Kingdom)

Read more
IUPAC Richter Prize Lecture
Medicinal Chemistry, Quo Vadis? - The Changing Climate In R&D
Dr Helmut BUSCHMANNDr Helmut BUSCHMANN
(PHARMA CONSULTING AACHEN, Aachen, Germany)

Read more
The UCB-Ehrlich Award for Excellence in Medicinal Chemistry
Small Molecule Control Of Intracellular Protein Levels
Prof. Craig CREWSProf. Craig CREWS
(UNIVERSITY OF YALE, New Haven, United States)
Portugal: the Right Place to build Partnerships in Health
Dr Joaquim CUNHADr Joaquim CUNHA
(HEALTH CLUSTER PORTUGAL, Maia, Portugal)

Read more
The Prous Institute-Overton and Meyer Award for New Technologies i Drug Discovery
Thermodynamics Assisted Drug Discovery
Dr György G. FERENCZYDr György G. FERENCZY
(HUNGARIAN ACADEMY OF SCIENCES, Budapest, Hungary)

Read more
Prof. Gyorgy KESERUProf. Gyorgy KESERU
(HUNGARIAN ACADEMY OF SCIENCES, Budapest, Hungary)

Read more
Plenary Lecture
Dr Sabine HADIDADr Sabine HADIDA
(VERTEX PHARMACEUTICALS, San Diego, United States)

Read more
The Nauta Award for Pharmacochemistry
Pursuing Compound Quality
Dr Paul LEESONDr Paul LEESON
(GLAXOSMITHKLINE, Nuneaton, United Kingdom)

Read more
High Resolution Mass Spectrometry in Clinical Proteomics
Prof. Dr Matthias MANNProf. Dr Matthias MANN
(MAX PLANCK INSTITUTE OF BIOCHEMISTRY, Martinsried, Germany)
Innovation Through Chemistry at the Interfaces of the Scientific Disciplines
Dr Martin MISSBACH
(NOVARTIS, Basel, Switzerland)
Partnership between Public and Private Sources: Pharma and IMI Perspective
Dr Paul Peter TAKDr Paul Peter TAK
(EFPIA, Brentford, United Kingdom)

Read more
Plenary Lecture
Prof. Hans WESTERHOFFProf. Hans WESTERHOFF
(VU UNIVERSITY AMSTERDAM, Amsterdam, The Netherlands)

Read more

Invited Speakers

Targeting Spore Germination to Prevent Clostridium Difficile Infections
Dr Ernesto ABEL-SANTOSDr Ernesto ABEL-SANTOS
(UNIVERSITY OF NEVADA, LAS VEGAS, Nevada, Las Vegas, United States)

Read more
Cyclic Peptides from the nature to the synthetic ones
Prof. Fernando ALBERICIOProf. Fernando ALBERICIO
(INSTITUTE FOR RESEARCH IN BIOMEDICINE, Durban , South Africa)

Read more
Sponging Off Nature for New Drug Leads
Prof. Raymond ANDERSENProf. Raymond ANDERSEN
(UNIVERSITY OF BRITISH COLUMBIA, Vancouver, Canada)

Read more
Omarigliptin: A Once-weekly Oral Antidiabetic Agent
Dr Tesfaye BIFTUDr Tesfaye BIFTU
(MERCK, Rahway, United States)

Read more
Design, Synthesis and Development of Lysophosphatidic Acid Receptor 1 (LPA1) PET Radioligands for Lung Receptor Occupancy Imaging
Dr Sam BONACORSIDr Sam BONACORSI
(BRISTOL-MYERS SQUIBB, Princeton, United States)

Read more
Invited Lecture
Dr Terry BOWLINDr Terry BOWLIN
(MICROBIOTIX, Worcester, United States)
Being More Certain About Uncertainty In Computational Toxicology Modeling
Dr Scott BOYERDr Scott BOYER
(KAROLINSKA INSTITUTET, Södertälje, Sweden)

Read more
Update on Chemotherapy of Tropical Diseases Caused by Protozoan Parasites
Prof. Reto BRUNProf. Reto BRUN
(SWISS TROPICAL AND PUBLIC HEALTH INSTITUTE, Basel, Switzerland)

Read more
Recent Advances In Asymmetric Catalysis
Prof. Erick M. CARREIRAProf. Erick M. CARREIRA
(ETH ZÜRICH, Zürich, Switzerland)

Read more
Inflammation, Obesity and Metabolic Disease
Dr Ajay CHAWLADr Ajay CHAWLA
(UNIVERSITY OF CALIFORNIA, San Francisco, United States)

Read more
Efficient Determination Of Protein-Ligand Standard Binding Free Energies And Permeabilities With A Computational Microcalorimeter
Dr Chris CHIPOTDr Chris CHIPOT
(UNIVERSITY OF ILLINOIS, Urbana, United States)

Read more
Binding Affinity Prediction from Molecular Simulation – Soon a Standard Method in Structure-Based Drug Design?
Dr Clara CHRISTDr Clara CHRIST
(BAYER PHARMA, Berlin, Germany)

Read more
Functional and Structural Insights into GPCR Allostery
Prof. Arthur CHRISTOPOULOSProf. Arthur CHRISTOPOULOS
(MONASH UNIVERSITY, Parkville, Australia)

Read more
BETting on Bromodomains: Developing Inhibitors of the Bromodomain-Acetyl-Lysine Interaction
Prof. Stuart CONWAYProf. Stuart CONWAY
(UNIVERSITY OF OXFORD, Oxford, United Kingdom)

Read more
New Stereoselective Organocatalytic Reactions for the Synthesis of Isoquinoline Alkaloids
Prof. Pier Giorgio COZZIProf. Pier Giorgio COZZI
(UNIVERSITY OF BOLOGNA, Bologna, Italy)

Read more
Exploring the Dynamics of Ligand-Protein Interactions using SPR Biosensors
Prof. Helena DANIELSONProf. Helena DANIELSON
(UPPSALA UNIVERSITY, Uppsala, Sweden)

Read more
Breaking The Equilibrium Dissociation Constant Into Fragments: The Use Of Binding Kinetics And Thermodynamics In The Development Of Selective Ligands.
Prof. Iwan DE ESCHProf. Iwan DE ESCH
(VU UNIVERSITY AMSTERDAM, Amsterdam, The Netherlands)

Read more
Exploiting Tumor Metabolic Vulnerabilities with Novel OxPhos Inhibitors
Dr Maria Emilia DI FRANCESCODr Maria Emilia DI FRANCESCO
(UTMD ANDERSON CANCER CENTER, Houston, United States)

Read more
Visualising Novel Macrolide Antibiotics Bound to Their Ribosomal Target
Prof. Stephen DOUTHWAITEProf. Stephen DOUTHWAITE
(UNIVERSITY OF SOUTHERN DENMARK, Odensen, Denmark)

Read more
A Rational Approach to the Development of Radioligands and PET Ligands for Drug Development
Dr Chad ELMOREDr Chad ELMORE
(ASTRAZENECA PHARMACEUTICALS, Mölndal, Sweden)

Read more
Epigenetic Drug Discovery: Small Molecule Inhibitors of Class IV Bromodomain Proteins
Prof. Paul FISHProf. Paul FISH
(UCL SCHOOL OF PHARMACY, London, United Kingdom)

Read more
Experiences with Natural Product Total Synthesis
Prof. Alois FÜRSTNERProf. Alois FÜRSTNER
(MAX PLANCK INSTITUT FUR KOHLENFORSCHUNG, Muelheim an der Ruhr, Germany)

Read more
Antimalarial Lead Discovery from phenotypic screening: Unraveling the Black Box
Dr Francisco-Javier GAMODr Francisco-Javier GAMO
(GLAXOSMITHKLINE, Madrid, Spain)

Read more
CNV1014802, a Novel Nav1.7 Selective State-Dependent Sodium Channel Blocker for the Treatment of Chronic Pain: From Discovery to Phase 2 Clinical Study
Dr Gerard GIBLINDr Gerard GIBLIN
(CONVERGENCE PHARMACEUTICALS, Cambridge, United Kingdom)

Read more
Mechanism-Based Prediction of Drug-Induced Liver Injury
Dr Christopher GOLDRINGDr Christopher GOLDRING
(UNIVERSITY OF LIVERPOOL, Liverpool, United Kingdom)

Read more
Integration of New Chemical Diversity and Design Approaches in Lead Generation
Dr Timothy GRESEDr Timothy GRESE
(ELI LILLY AND COMPANY, Indianapolis, United States)

Read more
CB2 Agonists Protect from Inflammation Related Kidney Damage and Fibrosis
Dr Uwe GRETHERDr Uwe GRETHER
(F. HOFFMANN-LA-ROCHE, Basel, Switzerland)

Read more
Mechanoenzymatics of Biomolecular Machines: Free Energies, Dynamics, Function
Prof. Helmut GRUBMÜLLERProf. Helmut GRUBMÜLLER
(MAX PLANCK INSTITUTE FOR BIOPHYSICAL CHEMISTRY, Göttingen, Germany)

Read more
An Introduction To Ion Channels As Drug Targets
Prof. Morten GRUNNETProf. Morten GRUNNET
(LUNDBECK, Valby, Denmark)

Read more
MedChemComm Prize Winner : Phage Selection Of Bicyclic Peptides For Therapeutic Application
Prof. Christian HEINISProf. Christian HEINIS
(ECOLE POLYTECHNIQUE FÉDÉRALE DE LAUSANNE (EPFL), Lausanne, Switzerland)

Read more
Discovery of the mGlu5 Negative Allosteric Modulator RO4917523
Dr Georg JAESCHKEDr Georg JAESCHKE
(F. HOFFMANN-LA ROCHE, Basel, Switzerland)

Read more
Development of New Anti-Infective Agents and a Novel Delivery Strategy
Prof. Reuben JIH-RU HWUProf. Reuben JIH-RU HWU
(NATIONAL TSING HUA UNIVERSITY, Hsinchu, Taiwan)

Read more
Synthesis of Anti-infective Cyclic Natural Products and Natural Product-like Compounds
Prof. Han-Young KANGProf. Han-Young KANG
(CHUNGBUK NATIONAL UNIVERSITY, Cheongju, Korea, South)

Read more
Bioactive Secondary Metabolites From The Soil And Marine-Derived Fungi Of The Genus Neosartorya
Prof. Anake KIJJOAProf. Anake KIJJOA
(UNIVERSITY OF PORTO, Porto, Portugal)

Read more
Pharmaceutical Protein & Peptide Engineering: From Once Daily To Once Weekly GLP-1 Dosing
Dr Jesper LAUDr Jesper LAU
(NOVO NORDISK, Maaloev, Denmark)

Read more
Translational Modeling in Support to Discovery and Early Development
Dr Thierry LAVEDr Thierry LAVE
(F.HOFFMANN-LA ROCHE LTD, Basel, Switzerland)
Pain-relieving Peptides Targeting Acid-Sensing Ion Channels
Dr Eric LINGUEGLIADr Eric LINGUEGLIA
(CNRS-UNIVERSITY OF NICE SOPHIA ANTIPOLIS, Valbonne, France)

Read more
Novel Anti-Cancer Treatment Targeting Vps34
Dr Jessica MARTINSSONDr Jessica MARTINSSON
(SPRINT BIOSCIENCE, Stockholm, Sweden)

Read more
High End Design for GPCRs: Combining Protein Structure, Biophysical Data and Computational Water Network Energies
Dr. Jonathan MASONDr. Jonathan MASON
(HEPTARES THERAPEUTICS, Welwyn Garden City, United Kingdom)
Non-Clinical Characterization And Clinical Translation Of LY2811376 And LY2886721
Dr Dustin James MERGOTTDr Dustin James MERGOTT
(ELI LILLY, Indianapolis, United States)

Read more
The Impact of Polypharmacology on Lead Generation
Dr Jordi MESTRESDr Jordi MESTRES
(IMIM AND UNIVERSITY POMPEU FABRA, Barcelona, Spain)
Therapeutic Opportunities Offered by the Excessive Lactate Production in Cancer
Prof. Filippo MINUTOLOProf. Filippo MINUTOLO
(UNIVERSITY OF PISA, Pisa, Italy)

Read more
Metalation of Polyfunctional Heterocyclic Compounds: Applications in Agrochemistry
Dr Marc MOSRINDr Marc MOSRIN
(BAYER CROPSCIENCE AG, Frankfurt am Main, Germany)

Read more
Successful Drug Discovery And Development Case Studies Of Protein Epitope Mimetics
Dr Daniel OBRECHTDr Daniel OBRECHT
(POLYPHOR, Allschwil, Switzerland)

Read more
A First In Class Chemical Probe For Family VIII Bromodomains
Dr Dafydd OWENDr Dafydd OWEN
(PFIZER, Cambridge, United States)

Read more
Novel Boron-containing Anti-infective Agents
Dr Jacob PLATTNERDr Jacob PLATTNER
(ANACOR PHARMACEUTICALS, Palo Alto, United States)

Read more
Restoration of Muscle Mass and Lifespan in a Mouse Model of Spinal Muscular Atrophy by Molecular Correction of SMN2 Splicing Defect
Dr Hasane RATNIDr Hasane RATNI
(F. HOFFMANN-LA ROCHE LTD, Basel, Switzerland)

Read more
Antimalarial Trioxolanes - Exploiting Peroxide Reduction For Parasite-Selective Drug Delivery
Dr Adam RENSLODr Adam RENSLO
(UNIVERSITY OF CALIFORNIA, San Francisco, United States)

Read more
Natural Products as Driving Force for Innovation in Pharmaceutical Research and Development
Dr Esther SCHMITTDr Esther SCHMITT
(NOVARTIS, Basel, Switzerland)

Read more
PET Imaging: Synthesis of Radiopharmaceuticals and their Application in Personalized Medicine and Drug Discovery
Dr Peter J.H. SCOTTDr Peter J.H. SCOTT
(UNIVERSITY OF MICHIGAN, Ann Arbor, United States)

Read more
The Ribosome as a Drug Target: Insights from Structural Investigations - Towards Rational Drug Design
Dr Moran SHALEV BEN AMIDr Moran SHALEV BEN AMI
(WEIZMANN INSTITUTE, Rehovot, Israel)

Read more
New Synthetic Routes of Nitrogen and Oxygen Heterocycles and Related Compounds
Prof. Artur M.S. SILVAProf. Artur M.S. SILVA
(UNIVERSITY OF AVEIRO, Aveiro, Portugal)

Read more
Discovery and Development of Surotomycin for the Treatment of C. difficile
Dr Jared SILVERMANDr Jared SILVERMAN
(CUBIST PHARMACEUTICALS, Lexington, United States)

Read more
CaV1.3-Selective L-Type Calcium Channel Negative Allosteric Modulators. Novel Therapeutics to Slow the Progression of Parkinson’s Disease
Prof. Rick SILVERMANProf. Rick SILVERMAN
(NORTHWESTERN UNIVERSITY, Evanston, United States)

Read more
Fragment-Based Discovery of BACE Inhibitors for Alzheimer’s Disease
Dr Andrew STAMFORDDr Andrew STAMFORD
(MERCK RESEARCH LABORATORIES, Rahway, United States)

Read more
Nanobody-Enabled Fragment Screening On Active-State Constrained GPCRs
Prof. Jan STEYAERTProf. Jan STEYAERT
(VUB, Brussels, Belgium)

Read more
1,1’-Spiro-Substituted Hexahydrofuroquinoline Derivatives As Potent And Polar Cholesteryl Ester Transfer Protein (CETP) Inhibitors
Dr Thomas TRIESELMANNDr Thomas TRIESELMANN
(BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG, Biberach an der Riss, Germany)

Read more
Strategies to Identify and Manage the Risks of Chemically Reactive Drug Metabolites
Prof. Nico VERMEULENProf. Nico VERMEULEN
(VU UNIVERSITY, Amsterdam, The Netherlands)

Read more
Cell-Permeable Peptide Therapeutics to Effectively Access Intracellular Targets in Cancer Stem Cells
Dr Jörg VOLLMER
(NEXIGEN, Cologne, Germany)

Read more
Medicinal Chemistry Optimisation Of Binding Kinetics
Prof. Mike WARINGProf. Mike WARING
(ASTRAZENECA, Newcastle upon Tyne, United Kingdom)

Read more
Fast and Safe Synthesis of Pharmaceutically Relevant Molecules
Prof. Thomas WIRTHProf. Thomas WIRTH
(UNIVERSITY OF CARDIFF, Cardiff, United Kingdom)

Read more
Starting Small, Thinking Big: The Application of Fragment Based Drug Discovery to Lead Generation
Dr Steve WOODHEADDr Steve WOODHEAD
(TAKEDA CALIFORNIA, San Diego, United States)

Read more

Oral Communications

Lectins as Targets in Antiadhesion Therapy - Example of DC-SIGN And FimH Antagonists
Prof. Marko ANDERLUHProf. Marko ANDERLUH
(UNIVERSITY OF LJUBLJANA, Ljubljana, Slovenia)
Covalent Modification of Histones by Nevirapine - A Plausible Pathway to Nevirapine-Induced Cancers?
Dr Alexandra ANTUNESDr Alexandra ANTUNES
(INSTITUTO SUPERIOR TÉCNICO, Lisbon, Portugal)

Read more
Interrogation the Bromodomain Family through Chemical Biology
Dr Steve BELLONDr Steve BELLON
(CONSTELLATION PHARMACEUTICALS, Cambridge, United States)

Read more
A HTS Assay Predicting Both Passive Intestinal Absorption and Affinity Constant Towards Human Serum Albumin in a Two End-Point Measurement
Mr Alban BUJARD
(UNIVERSITY OF GENEVA, Geneva, Switzerland)
The Discovery of AZD5069; a CXCR2 Antagonist In Phase II Clinical Trials for the Treatment of Asthma
Dr Rhona COXDr Rhona COX
(ASTRAZENECA, Mölndal, Sweden)

Read more
CHF-6001, an Inhaled PDE4 Inhibitor for Asthma and COPD: Synthesis, In Vitro and In Vivo Characterization
Dr Maurizio DELCANALEDr Maurizio DELCANALE
(CHIESI, Parma, Italy)

Read more
Structure-Guided Design of Potent, Selective, Orally Bioavailable Tankyrase Inhibitors
Dr Erin DIMAURODr Erin DIMAURO
(AMGEN, Cambridge, United States)

Read more
Antagonists of the Pseudomonas Quinolone Signal Receptor (PQSR) as Promising Anti-Virulence Agents
Dr Martin EMPTINGDr Martin EMPTING
(HELMHOLTZ-INSTITUTE F. PHARMACEUTICAL RESEARCH SAARLAND, Saarbrücken, Germany)

Read more
P-Glycoprotein/Membrane Role on Multidrug Resistance: Insights from In Silico Studies
Mr Ricardo FERREIRAMr Ricardo FERREIRA
(FACULTY OF PHARMACY, UNIVERSITY OF LISBON, Lisbon, Portugal)

Read more
Covalent Agonists Facilitating Crystallisation of GPCRs
Prof. Peter GMEINERProf. Peter GMEINER
(FRIEDRICH ALEXANDER UNIVERSITY, Erlangen, Germany)

Read more
CRTH2: Can Residence Time Help?
Dr Elena GOMEZDr Elena GOMEZ
(ALMIRALL, BARCELONA, Spain)

Read more
Discovery of Ivacaftor (Vx-770), a Cftr Potentiator for the Treatment of Cystic Fibrosis in G551d Patients
Dr Sabine HADIDADr Sabine HADIDA
(VERTEX PHARMACEUTICALS, San Diego, United States)

Read more
Discovery of the First and Only Small Molecule Il-17 Blockers
Dr Nils HANSENDr Nils HANSEN
(VIPERGEN, Copenhagen, Denmark)

Read more
Discovery of TD-5959 (Batefenterol/GSK-961081): A First-in-Class Dual Pharmacology Multivalent Muscarinic Antagonist and Beta-2 Agonist (MABA) for the Treatment of COPD
Dr Adam HUGHESDr Adam HUGHES
(THERAVANCE INC., South San Francisco, United States)

Read more
The Discovery of APD334, a Selective S1P1 Functional Antagonist
Dr Robert JONESDr Robert JONES
(ARENA PHARM, SAN DIEGO, United States)

Read more
Quantitative Imaging of Mglu5 Allosteric Binding Site and its Occupancy by Positron Emission Tomography with The Novel Fluorine-18 Labelled Probe [18f]Pss232
Dr Stefanie KRAMERDr Stefanie KRAMER
(ETH ZÜRICH, Zürich, Switzerland)

Read more
Biomarkers after Bacteriochlorin Based Photodynamic Therapy against Cancer
Dr Martyna KRZYKAWSKA-SERDADr Martyna KRZYKAWSKA-SERDA
(FACULTY OF BIOCHEMISTRY, BIOPHYSICS AND BIOTECHNOLOGY, JAGIELLONIAN UNIVERSITY, Krakow, Poland)

Read more
Design, Synthesis and Biological Evaluation of Potent and Selective Class IIA Histone Deacetylase Inhibitors as a Potential Therapy for Huntington's Disease
Dr Christopher LUCKHURSTDr Christopher LUCKHURST
(BIOFOCUS, Saffron Walden, United Kingdom)

Read more
Allosteric Protein Kinases Inhibitors for Neurodegenerative Diseases Therapies
Prof. Ana MARTINEZProf. Ana MARTINEZ
(INSTITUTO DE QUIMICA MEDICA-CSIC, Madrid, Spain)

Read more
Discovery and Characterization of A-366, a Novel, Potent and Highly Selective Inhibitor of Histone Methyltransferase G9a
Dr Michael MICHAELIDESDr Michael MICHAELIDES
(ABBVIE, North Chicago, United States)

Read more
Metal Assisted Synthetic Approaches to Heterocyclic Small Molecules for the Treatment of Cardiovascular Diseases
Prof. Marko D. MIHOVILOVICProf. Marko D. MIHOVILOVIC
(VIENNA UNIVERSITY OF TECHNOLOGY, Vienna, Austria)

Read more
Development of Novel Building Blocks to Accelerate Drug Discovery
Dr Pavel MYKHAILIUKDr Pavel MYKHAILIUK
(ENAMINE, Kyiv, Ukraine)

Read more
Discovery of Small Molecule Rorγ Modulators for the Treatment of Autoimmune Diseases
Dr Frank NARJESDr Frank NARJES
(ASTRAZENECA, Mölndal, Sweden)

Read more
Discovery of GPR103 Ligands Demonstrating the Anorexigenic Effect in vivo of GPR103 Antagonism
Dr Anneli NORDQVISTDr Anneli NORDQVIST
(ASTRAZENECA, Mölndal, Sweden)

Read more
The Evolution of an in vivo Efficacious Bace1 Inhibitor
Dr Daniel OEHLRICHDr Daniel OEHLRICH
(JOHNSON & JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT, Beerse, Belgium)

Read more
EFMC Prize for a Young Medicinal Chemist in Academia
Inhibitors and Substrates of the Human Lysine Deacylase Enzymes
Prof. Christian A. OLSENProf. Christian A. OLSEN
(UNIVERSITY OF COPENHAGEN, Copenhagen, Denmark)

Read more
Cadazolid: A New Antibiotic in Development for the Treatment of Clostridium Difficile-Associated Diarrhea (CDAD)
Dr Philippe PANCHAUDDr Philippe PANCHAUD
(ACTELION PHARMACEUTICALS LTD, Allschwil, Switzerland)

Read more
EFMC Prize for a Young Medicinal Chemist in Industry
Design, Synthesis and Properties of Potent Inhibitors of Pseudomonas Aeruginosa Deacetylase LpxC
Dr Grazia PIIZZIDr Grazia PIIZZI
(NOVARTIS PHARMA, Basel, Switzerland)

Read more
Identifying Selective Inhibitors of FGFR4 Kinase
Dr Kurt PIKEDr Kurt PIKE
(ASTRAZENECA, Cambridge, United Kingdom)

Read more
Crystallographic Structures Enable the Discovery of Selective 5-Ht1b Receptor Ligands through Virtual Screening
Dr David RODRIGUEZ DIAZDr David RODRIGUEZ DIAZ
(STOCKHOLM UNIVERSITY, Solna, Sweden)

Read more
From Malaysian Biodiversity to the Total Synthesis of Dual Inhibitors of BCL-XL and MCL-1 Anti-Apoptotic Protein
Dr Fanny ROUSSIDr Fanny ROUSSI
(ICSN - CNRS, Gif sur Yvette, France)

Read more
Discovery of BAY 1002670 - A Highly Potent and Selective Progesterone Receptor Modulator for Gynecological Therapies
Dr Wolfgang SCHWEDEDr Wolfgang SCHWEDE
(BAYER, Berlin, Germany)

Read more
Cebranopadol, a Novel, Potent Analgesic
Dr Henning STEINHAGENDr Henning STEINHAGEN
(GRÜNENTHAL, Verona, Italy)

Read more
Novel Potent Inhibitors of the Histone Demethylase KDM1A
Dr Paola VIANELLODr Paola VIANELLO
(EUROPEAN INSTITUTE OF ONCOLOGY, Milan, Italy)

Read more
Discovery of BAY 85-8501, a Novel and Highly Potent Induced-Fit Binder of Human Neutrophil Elastase for Pulmonary Diseases
Dr Franz VON NUSSBAUMDr Franz VON NUSSBAUM
(BAYER PHARMA, Berlin, Germany)

Read more
Antibodies as Tools to Enable Small Molecule Drug Discovery
Dr Marta WESTWOODDr Marta WESTWOOD
(UCB, Slough, United Kingdom)

Read more
Improving Physiochemical Properties of a Lapatinib-Based Lead Compound that Targets Trypanosoma Brucei
Prof. Jennifer WOODRINGProf. Jennifer WOODRING
(NORTHEASTERN UNIVERSITY, Boston, United States)

Read more
Novel Inhibitors of Alzheimer's Associated Beta-Secretase-Clusters of Heparan Sulfate
Dr Olga ZUBKOVADr Olga ZUBKOVA
(VICTORIA UNIVERSITY OF WELLINGTON, Lower Hutt , New Zealand)

Read more

With the support of

Gold Sponsors

Silver Sponsors

Bronze Sponsors

Award Sponsors

Concert Sponsor

Travel Grants Sponsors

Premium Exhibitors

Media Partners

Copyright 2019 LD Organisation sprl  |  rue Michel de Ghelderode 33/02 B-1348  Louvain-la-Neuve (Belgium)  Tel. +32 (0)10 45 47 77  |   |  VAT: BE 0464819842
Developed and powered by Antalys